Completed PHASE2 INTERVENTIONAL 1-arm NCT02323685

Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)

Single Escalating-dose, Open-label Study to Assess the Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) After Acute Aneurysmal Subarachnoid Hemorrhage (SAH)

Sponsor: Prolong Pharmaceuticals

Conditions Cerebral Ischemia

Interventions SANGUINATE™

Updated 7 times since 2017 Last updated: Oct 26, 2016 Started: Dec 31, 2014 Primary completion: Jun 30, 2016 Completion: Oct 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02323685, this PHASE2 trial focuses on Cerebral Ischemia and remains completed. Sponsored by Prolong Pharmaceuticals, it has been updated 7 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Prolong Pharmaceuticals

Data source: Prolong Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• St Louis, United States